Your browser doesn't support javascript.
loading
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
Chen, Jennifer H; Addanki, Sridevi; Roy, Dhruvajyoti; Bassett, Roland; Kalashnikova, Ekaterina; Spickard, Erik; Kuerer, Henry M; Meas, Salyna; Sarli, Vanessa N; Korkut, Anil; White, Jason B; Rauch, Gaiane M; Tripathy, Debu; Arun, Banu K; Barcenas, Carlos H; Yam, Clinton; Sethi, Himanshu; Rodriguez, Angel A; Liu, Minetta C; Moulder, Stacy L; Lucci, Anthony.
Afiliación
  • Chen JH; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Addanki S; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Roy D; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Bassett R; Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Kalashnikova E; Natera, Inc, Austin, TX, USA.
  • Spickard E; Natera, Inc, Austin, TX, USA.
  • Kuerer HM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Meas S; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Sarli VN; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US.
  • Korkut A; Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • White JB; Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Rauch GM; Abdominal Imaging Department, MD Anderson Cancer Center, Houston, TX, USA.
  • Tripathy D; Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Arun BK; Breast Medical Oncology and Clinical Cancer Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Barcenas CH; Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Yam C; Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Sethi H; Natera, Inc, Austin, TX, USA.
  • Rodriguez AA; Natera, Inc, Austin, TX, USA.
  • Liu MC; Natera, Inc, Austin, TX, USA.
  • Moulder SL; Medical Oncology, Eli Lilly and Company, Indianapolis, IN, USA.
  • Lucci A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 7.6000, Unit 1484,, Houston, TX, 77030, US. alucci@mdanderson.org.
BMC Cancer ; 24(1): 1016, 2024 Aug 16.
Article en En | MEDLINE | ID: mdl-39148033
ABSTRACT

BACKGROUND:

Triple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) could predict response and long-term outcomes to neoadjuvant chemotherapy (NAC).

METHODS:

Patients with TNBC were enrolled between 2017-2021 at The University of Texas MD Anderson Cancer Center (Houston, TX). Serial plasma samples were collected at four timepoints pre-NAC (baseline), 12-weeks after NAC (mid-NAC), after NAC/prior to surgery (post-NAC), and one-year after surgery. ctDNA was quantified using a tumor-informed ctDNA assay (SignateraTM, Natera, Inc.) and CTC enumeration using CellSearch. Wilcoxon and Fisher's exact tests were used for comparisons between groups and Kaplan-Meier analysis used for survival outcomes.

RESULTS:

In total, 37 patients were enrolled. The mean age was 50 and majority of patients had invasive ductal carcinoma (34, 91.9%) with clinical T2, (25, 67.6%) node-negative disease (21, 56.8%). Baseline ctDNA was detected in 90% (27/30) of patients, of whom 70.4% (19/27) achieved ctDNA clearance by mid-NAC. ctDNA clearance at mid-NAC was significantly associated with pathologic complete response (p = 0.02), whereas CTC clearance was not (p = 0.52). There were no differences in overall survival (OS) and recurrence-free survival (RFS) with positive baseline ctDNA and CTC. However, positive ctDNA at mid-NAC was significantly associated with worse OS and RFS (p = 0.0002 and p = 0.0034, respectively).

CONCLUSIONS:

Early clearance of ctDNA served as a predictive and prognostic marker in TNBC. Personalized ctDNA monitoring during NAC may help predict response and guide treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Neoadyuvante / Neoplasias de la Mama Triple Negativas / ADN Tumoral Circulante / Células Neoplásicas Circulantes Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Neoadyuvante / Neoplasias de la Mama Triple Negativas / ADN Tumoral Circulante / Células Neoplásicas Circulantes Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido